Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 futibatinib plus PD-1 antibody-based standard-of-care therapy in advanced esophageal cancer or pancreatic ductal adenocarcinoma
2023-507516-12-00Phase 2Authorised
- Sponsor
- Taiho Oncology
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of futibatinib in esophageal cancer and pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by Taiho Oncology. Primary endpoint: Objective response rate. Planned start May 2024; status: authorised.
02
Drugs
futibatinib
03
Conditions
esophageal cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-507516-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507516-12-00.